CSL and Vitaeris Inc have announced they have entered into a strategic collaboration and purchase option agreement to expedite the development of clazakizumab, an anti-IL6 MAB, formerly ALD518, as a therapeutic option for solid organ transplant rejection.
Clazakizumab is a humanised, monoclonal antibody that binds to and inhibits Interleukin-6 (IL-6), an important driver of the inflammatory response and known to play a key role in transplant rejection, the joint release stated.
The deal will see US$15m paid by CSL along with milestone payments "over several years" and includes an exclusive option for CSL to acquire Vitaeris.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Dec 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Dec 17
